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Abstract Recent studies investigating pituitary function
after non-sellar brain tumor surgery showed that up to
38.2% of patients have pituitary insufficiency (PI). It has
been assumed that the operation causes the PI, but
preoperative hormone testing, which would have been
necessary to prove this assumption, was not performed.
The objective of this study is to answer the question if
indeed microsurgery is the culprit of PI in patients with
operatively treated non-sellar brain tumors. In this prospec-
tive trial, 54 patients with supratentorial non-sellar tumors
were included. The basal levels of cortisol, prolactin,
testosterone, estrogen, IGF-1, fT3, fT4, STH, TSH, ACTH,
FSH, and LH were recorded preoperatively on days 1 and 7
after surgery. If basal hormone screening revealed an
abnormality, a releasing hormone assay was performed.
Before surgery, 24 of the 54 patients (44.4%) already had
PI. Additional 25 patients showed either hypocortisolism or
hypothyreoidism. As those patients had been pre-treated
with dexamethasone and L-thyroxine, these findings were
considered not to represent PI but drug effects. Hormone
testing on days 1 and 7 after surgery revealed no changes.
With 44.4% PI is a frequent finding in brain tumor patients
already before surgery. The factors causing preoperative PI
remain yet to be identified. The endocrine results after
surgery are unchanged which rules out that surgery is the
cause of PI.
Keywords Pituitary insufficiency.Non-sellar brain tumor.
Quality of life.Brain tumor surgery
Introduction
Pituitary insufficiency (PI) is a well-known sequel of the
surgical management of intra- and parasellar tumors [1–13].
Surprisingly, PI also has been described in 38.2% to 43.2%
of the patients who underwent surgery for gliomas,
meningiomas, and neurinomas in distance to the sellar
region [5, 14, 15] .T h o s ed e f i c i t sh a v eb e e np r o p o s e dt ob e
a result of the surgical intervention. The authors assumed
that brain damage at the tumor site and brain damage on the
way to the tumor causes PI [15]. However, the assumption
of surgery-related PI has to be questioned, because
hormone testing was only done after surgery, which
precludes the identification of PI-inducing factors not
related to surgery and possibly already existing preopera-
tively. Apart of this, damage of healthy brain is not
common in tumor surgery today, especially when dealing
with extraaxial tumors. To finally answer the question if PI
in brain tumor patients is caused indeed by surgery, we
performed a prospective clinical trial in which the hormone
status was tested before and twice after surgery. As it is
known from the studies of PI after brain trauma and
aneurysmal subarachnoid hemorrhage that reduced quality
of life (QoL) could be a subtle indicator of PI, SF-36 testing
was additionally performed [6, 8, 12, 16–21].
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Study design
This prospective study protocol was approved by the
medical ethic committee of the University of Giessen and
Marburg GmbH. Fifty-four patients were enrolled in this
prospective clinical study. An informed consent was
obtained from all patients to participate. Exclusion criteria
consisted of the following: (1) age <18 years; (2) cognitive
or speech problems; (3) missing legal competence; (4)
pituitary adenomas, craniopharyngeomas, and tumors close
to or infiltrating into hypothalamus and hypophyseal stalk;
and (5) infratentorial tumors.
Patients (Table 1)
The study comprised 54 patients (28 men, 26 women,
median age 56.8 years) with supratentorial intra- and
extraaxial tumors undergoing microsurgery. There were 29
patients (53.7%) with malignant glioma (WHO grades III
and IV), three (5.6%) with low-grade glioma (WHO grade
II), 15 (27.8%) with meningioma, four (7.4%) with
metastases, two (3.7%) with non-Hodgkin’s lymphoma,
and one patient (1.9%) with ganglioglioma. In seven
patients, a recurrent tumor was treated.
Preoperative medication, pretreatment
The following drugs with potential effect on pituitary
function or the patient’s cognitive status were taken by the
patients prior to surgery: dexamethasone in 33 (61.1%),
thyroxine in 11 (20.4%), antiepileptic medication (valproic
acid, carbamazepine, and lamotrigine) in 12 (22.2%),
neuroleptic medication in three (5.6%), antidepressants in
four (7.4%), benzodiazepines in three (5.6%), L-dopamine
in one (1.9%), and anti-diabetic medication (insulin or
glibenclamide) in five (9.3%) cases. In 21 patients, more
than one drug was given. Nine patients were admitted
without any pre-medication.
Five patients underwentprior combined radio-chemotherapy,
two patients underwent radiation, and one patient
underwent chemotherapy only. One patient was treated
with combined radio-chemotherapy for acute lymphatic
leukemia during childhood.
Endocrine evaluation
Venous blood samples (10 ml) drawn in a lithium-
heparinized syringe and EDTA syringe, between 8 and
10 a.m., were analysed for basal hormone concentrations.
We determined the basal concentrations of cortisol, insulin-
like growth factor 1 (IGF-1), prolactin (PRL), testosterone,
estrogen, free thyroxine (fT3, fT4), follicle-stimulating
hormone (FSH), leuteinizing hormone (LH), thyroid-
stimulating hormone (TSH), adrenocorticotropic hormone
(ACTH), and growth hormone (GH). Patients who had an
abnormal basal hormonal value underwent a stimulation test.
Pituitary stimulation tests were conducted in a standard
manner using releasing hormones in the following order:
100 μg growth hormone-releasing hormone (GHRH),
100 μg luteinizing hormone-releasing hormone, 100 μg
corticotropin-releasing hormone (CRH), and 200 μg
thyrotropin-releasing hormone. Blood samples were drawn
at 0, 15, 30, 60, and 90 min after injection through a
Table 1 Description of the patient sample
Average age Years 56.8
Min. age Years 21
Max. age Years 84
Gender n (%)
Female 26 48.0
Male 28 52.0
Diagnosis n (%)
GBM 21 38.9
Meningeoma 15 27.8
Metastasis 4 7.4
NHL 2 3.7
Ganglioglioma 1 1.9
Oligoastrocytoma WHO
a II 1 1.9
Oligoastrocytoma WHO
a III 2 3.7
Astrocytoma WHO
a II 1 1.9
Astrocytoma WHO
a III 2 3.7
Oligodendroglioma WHO
a II 1 1.9
Oligodendroglioma WHO
a III 2 3.7
Gliosarcoma 2 3.7
Location n (%)
Frontal lobe 14 27.8
Temporal lobe 12 22.2
Parietal lobe 5 9.3
Occipital lobe 3 5.6
Fronto-parietal 5 9.3
Fronto-temporal 1 1.9
Temporo-occipital 2 3.7
Parieto-occipital 3 5.6
Sphenoid wing 2 3.7
Falcine 1 1.9
Tentorial 1 1.9
Orbital 1 1.9
Basal ganglia 1 1.9
Intraventricular 2 3.7
GBM glioblastoma multiforme, NHL non-Hodgkin’s lymphoma
aWHO world health organization
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hormone concentrations) were drawn on the first and
seventh postoperative day.
Normal reference values were: prolactin 60–525 μLU/ml
for women and 20–350 μLU/ml for men, testosterone 300–
1,000 ng/dL, estrogen for women aged 14–55 years
18–571 pg/ml, estrogen for women older than 55 years 7–
44 pg/ml, fT3 2.2–4.5 pg/ml, fT4 0.8–1.8 ng/dL, age-adjusted
IGF-1 55–483 ng/ml, cortisol 5–20 μg/dL, luteinizing
hormone in the follicular phase 2–13 mU/ml, midcycle peak
15–79 mU/ml,lutealphase 1–19mU/ml and postmenopausal
11–61 mU/ml, FSH in the follicular phase 3–12 mU/ml,
midcycle peak 8–23 mU/ml, luteal phase 2–12 mU/ml and
postmenopausal36–157mU/ml,ACTH18–55 pg/ml, growth
hormone <6 ng/ml, and TSH 0.4–4.0 mU/L.
Definition of hormonal impairment
Secondary hypothyroidism was defined as low fT4 or fT3
concentrations with normal or low normal TSH levels.
Secondary hypogonadism was defined as low testosterone or
estrogenlevels withlow ornormalFSHorLHlevels.Primary
hypogonadism was diagnosed if gonadotropins were elevated
with low testosterone levels in men and amenorrhea in
premenopausal women. Postmenopausal women could not
be evaluated in this regard. Pituitary GH deficiency was
defined as low IGF-1 and STH combined with an insufficient
GHRH stimulation test. Secondary adrenal insufficiency was
diagnosed if patients presented with low morning cortisol
concentrations and insufficient stimulation to CRH. Patients
pre-treated with dexamethasone were excluded.
Evaluation of cranial magnetic resonance imaging scans
The preoperative magnetic resonance imaging (MRI) scans
were evaluated for the localization of the lesion,
corresponding lesion size (in cubic centimeters), potential
midline shift (in millimeters), and the minimal distance
between the tumor and the pituitary stalk.
Quality of life assessment
The SF-36 health questionnaire was used to evaluate the
patient’s QoL. The transformed scores were used for further
analysis.
Statistical analysis
All statistical tests were performed using Statistica 8 (Statsoft,
Hamburg, Germany). Univariate analyses were performed
with Student’s t test for continuous parameters and the
chi-square test for categorical parameters. A p value<0.05
was considered significant.
Results
Preoperative pituitary function
Before surgery, 24 of the 54 patients (44.4%) showed PI.
Twenty of the 24 patients with PI had a deficiency in one
(secondary hypogonadism in 13, secondary hypothyroidism
in six, and growth hormone deficiency in one patient) and
four in two pituitary axes (hypothyroidism and secondary
hypogonadism in two patients, secondary hypogonadism
and growth hormone deficiency and secondary hypogonadism
and secondary adrenal insufficiency in one patient each). In
addition to the 17 patients with secondary hypogonadism, five
patients had primary hypogonadism with either increased
levels of both FSH and LH (n=1) or increased levels of FSH
or LH (n=2 each). The median age of the patients with
primary hypogonadism was 62.8 years and that of patients
with secondary hypogonadism was 56.6 years. Six patients
were diagnosed with primary hyperthyroidism, three with
hypercortisolism, four with excessive release of either FSH,
LH, or both. Two patients showed an increased ACTH level
and eight patients an increased IGF-1.
Another four patients had secondary hypothyroidism,
and two patients revealed increased levels of fT3 or fT4.
However, these patients were pre-treated with L-thyroxine.
Hypocortisolism was found in 19 patients, which were pre-
treated with dexamethasone. Therefore, these endocrine
findings were considered not to be related to PI but to drug
intake. All patients who received prior chemotherapy,
radiotherapy, or combined treatment showed normal basal
hormonal screening.
Eleven patients (45.8%) underwent pituitary stimulation
test due to abnormal basal hormone levels. The remaining
patients refused stimulation. Stimulation test did not detect
new insufficiencies. Increased levels of PRL, LH, FSH,
cortisol, and TSH in 7, 7, 1, 1, and 6 cases, respectively,
were found.
Postoperative pituitary function
Regarding the blood samples drawn on the first and seventh
postoperative day, we did not find any abnormalities that
differed from the preoperative laboratory analyses (Table 2).
Pituitary function and neuroradiological findings
In patients with PI, a frontal tumor location was seen in
eight, fronto-parietal in one, temporal in seven, parietal in
three, parieto-occipital in two patients, and occipital,
intraventricular, and an intraorbital location in one patient
each. In patients without PI, a frontal location was found in
seven, fronto-parietal in four, temporal in seven, temporo-
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and at the sphenoid wing in two patients. In one patient
each, the tumor location was found in the basal ganglia,
falcine, and at the tentorium. In patients with PI, the
predominant tumor location was frontal. The finding did
not reach statistical significance since 12 patients without
PI also presented with tumors located predominantly in the
frontal lobe (p=0.925). Median tumor size was 30.1 mm
3
(range, 0.4–130.7 mm
3). Dichotomizing tumor volume into
less and more than 30.1 mm
3, no statistical significant
relation between tumor volume and PI (sensitivity, 0.52;
specificity, 0.32; p=0.394) could be seen. Midline shift was
found in 19 cases with a median shift of 5.8 mm (range,
2.2–7.8 mm). The midline shift was shown in 12 patients
with PI and seven patients without PI. Statistical analysis
did not reveal significance (p=0.153) regarding the
correlation of PI and midline shift with a sensitivity of
0.48 and a specificity of 0.29. The median distance between
the tumor and the pituitary stalk was 63.1 mm (range, 26.4–
90.0 mm). Dichotomizing into a distance of less and more
than 63.1 mm, no significant correlation between tumor or
pituitary stalk distance and PI (p=0.210; sensitivity, 0.61;
specificity, 0.61) could be seen.
Pituitary function and QoLs
AccordingtothestandardizedtransformedscalesoftheSF-36
mean values (in percentage) regarding emotional role,
physical role, body pain, vitality, social function, physical
function, general health, and mental health were 27.4%,
27.3%, 60.6%, 43.0%, 59.8%, 47.9%, 46%, and 53.3%,
respectively. The results demonstrate that the emotional and
physical roles as well as vitality are the values that are being
most affected in brain tumor patients.
As demonstrated in Table 3, patients without PI had
higher mean values according to the SF-36 test results, but
only in the subgroup “physical functioning” a statistically
significant difference could be found (p=0.01). Neuropsy-
chological complaints were primarily associated with
glioblastoma multiforme (GBM), which did not reach
statistical significance.
Discussion
PI after aneurysmal subarachnoid hemorrhage and brain
trauma
Pituitary function is well investigated in patients after
aneurysmal subarachnoid hemorrhage and brain trauma,
and PI is a frequent finding. The majority of these patients
suffer from GH deficiency. The attempt was made to
explain the cause of the endocrine dysfunction. As in non-
survivors, necrosis, infarction, and bleedings were often
seen in the hypothalamus and the pituitary gland, PI in the
survivors was believed to be related to similar but less
severe lesions. Furthermore, neurosurgical clipping was
attributed to contribute to PI at least in aneurysms of the
anterior circulation [22, 23].
PI and brain surgery—previous studies
De Marinis et al. showed that 16 of 37 patients (43.2%)
who underwent neurosurgical intervention for benign
tumors, not involving the hypothalamic–pituitary region,
also had PI [5]. These data have been confirmed by
Schneider and co-workers who examined the endocrine
function in 68 patients with non-pituitary intracranial
tumors, among which had been benign and non-benign
intraaxial tumors, even in the posterior fossa. 38.2% of the
patients had PI after the neurosurgical intervention in
combination with radiotherapy, chemotherapy, or both
Table 2 Mean/range of pre- and postoperative results (first and seventh postoperative day)
Hormone Unit Pre-op mean value (range) Post-op 1st day mean value (range) Post-op 7th day mean value (range)
Cortisol μg/dl 8.6 (0.4–23.7) 8.6 (0.40–28.30) 9.0 (0.4–42.3)
IGF-1 ng/ml 150.5 (52.0–373.0) 131.7 (44.0–320.0) 132.53 (33.0–311.0)
PRL μlU/ml 151.1 (20.0–407.0) 159.4 (20.0–676.0) 163.09 (53.0–354.0)
Testosterone ng/dl 274.8 (38.0–781.0) 206.0 (50.0–451.0) 213.59 (50.0–670.0)
fT3 pg/ml 2.7 (1.4–3.8) 2.4 (1.4–3.4) 2.4 (0.5–3.4)
fT4 ng/dl 1.4 (0.8–2.1) 1.3 (0.8–1.9) 1.32 (0.2–2.1)
FSH mU/ml 19.1 (0.6–86.5) 17.1 (0.6–73.0) 16.41 (0.3–73.0)
LH mU/ml 12.3 (1.3–91.8) 11.6 (0.8–91.8) 10.5 (0.1–91.8)
TSH mU/l 0.9 (<0.01–3.0) 0.8 (<0.01–2.4) 0.85 (<0.01–2.4)
ACTH pg/ml 15.5 (<5.0–59.1) 15.1 (<5.0–45.7) 15.6 (<5.0–59.1)
IGF-1 insulin-like growth factor 1, PRL prolactin, fT3, fT4 free thyroxine, FSH follicle-stimulating hormone, LH leuteinizing hormone, TSH
thyroid-stimulating hormone, ACTH adrenocorticotropic hormone
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endocrinealterations.Inbothstudies,secondaryhypogonadism
was the most common finding of PI. Second most common
finding was GH deficiency. The fact that PI was more common
in patients who underwent neurosurgical treatment only than in
those with additional other treatments leads to the assumption
that the neurosurgical procedure plays a major role in the
development of PI [15]. It was believed that surgical trauma at
t h et u m o rs i t ea n do nt h ew a yt ot h et u m o rc a u s e sP I .O t h e r
potential factors of PI, which had been considered by the
authors, were tumor infiltration of and metastases in the
hypothalamic–hypophyseal area.
Unfortunately, both studies have substantial flaws. First,
hormonal testing was only performed after the operation.
Thus, the conclusion that surgery is the culprit of the
diagnosed PI cannot be drawn. Second, damage to normal
brain is rare in extraaxial tumors, not the rule in intraaxial
tumors, and is not explainable in tumors of the fourth
ventricle. Third, tumor infiltration or metastases do not
remain unrecognized in times of advanced MR imaging.
The immature study design of the two studies stimulated
the initiation of the present prospective trial.
PI and brain surgery—present study
The major finding of the present study is that more than
40% of the patients of our study population already
presented with PI before neurosurgical treatment, which
leads to the conclusion that factors other than the operation
itself cause the pituitary dysfunction. As there are no
statistically significant differences, concerning tumor volume,
midline shift, and localization had been seen between the
group of patients with and without PI, the authors even do not
believe that tumor-related effects to surrounding brain tissue
are causative for PI. To further support this assumption, a
study including other cancer patients undergoing surgery
outside the brain and patients with the need for brain surgery
other than cancer could serve as control groups in a second
study trial. Secondary, hypogonadism was the most common
finding in pre- and postoperative testing in the present study,
which is somewhat in line with the postoperative findings of
Schneider et al. and de Marinis et al. [5, 15] but which is in
contrast to the results in aneurysmal subarachnoid hemor-
rhage (SAH) and brain trauma with GH deficiency predom-
inance. Possibly, this discrepancy could be explained by the
fact that patients with brain tumors are older than those with
SAH and head injury. The prevalence of hypogonadism in
healthy males aged 45 years or more has been estimated to
be 38.7%, and hypogonadism could be more the result of
advanced age than of tumor growth or tumor surgery [24]. If
this holds true and if all male patients aged 45 years or more
with secondary hypogonadism in the present study popula-
tion would be excluded, the rate of PI in brain tumor patients
would drop from 44.4% to only 20.4%. Furthermore, risk
Table 3 Quality of life in patients with and without pituitary insufficiency
n Pituitary insufficiency n No pituitary insufficiency p value
Demographics 24 30
Age (average) 24 59.8 30 54.3
Females (n=26) 5 9.3% 21 38.9% 0.001
Males (n=28) 19 35.2% 9 16.7% 0.001
Quality of life evaluation 20 28
Nervousness 20 30.0% 28 32.1% 0.86
Irritability 20 25.0% 28 25.0% 0.74
Depression 20 10.0% 28 14.3% 0.74
Fatigue 20 80.0% 28 35.7% 0.006
Libido decreased 20 35.0% 28 14.3% 0.18
Weight gain 20 15.0% 28 14.3% 0.73
Increased perspiration 20 15.0% 28 7.1% 1.00
SF-36 questionnaire score (mean±SD) 20 28
Role emotional 20 20.83±23.49 28 32.14±19.74 0.28
Role physical 20 18.75±20.07 28 33.48±19.26 0.50
Bodily pain 20 51.54±32.78 28 67.08±20.89 0.46
Vitality 20 36.25±16.34 28 47.77±15.07 0.44
Social function 20 50.00±20.00 28 66.79±18.29 0.27
Physical function 20 42.48±21.92 28 51.79±17.84 0.01
General health 20 36.76±13.14 28 53.03±14.10 0.20
Mental health 20 46.17±15.76 28 58.33±12.88 0.25
Neurosurg Rev (2011) 34:509–516 513factors such as obesity, diabetes, hypertension, rheumatoid
arthritis, hyperlipidemia, osteoporosis, chronic obstructive
pulmonary disease, and chronic pain have been identified in
the development of hypogonadism [24]. Thirteen of the 22
patients of our study population with primary or secondary
hypogonadism had one or more of these risk factors, which
mean that the possibility that hypogonadism is linked to PI is
further being reduced.
If so, an even higher proportion of patients with PI
would have underlined our results even more. Concerning
patients with supratentorial extrasellar tumors, further
studies are warranted to define the amount of patients
suffering from surgery-induced PI or improvement of PD.
QoL and PI
Reduced mental health as well as disturbed emotional and
social functioning, resulting in reduced QoL, are quite
common in patients with PI and mostly are related to GH
deficiency [15]. Thus, posttraumatic and posthemorrhagic
mental, emotional, and social disorders are very similar to
those of adult onset GH deficiency [25, 26]. As mentioned
above, PI is frequent after head trauma and SAH, which
means that not all these disorders in those patients could be
related to the trauma or the bleeding. Subnormal vigor
scores in multiple pituitary hormone deficiency are attrib-
uted to reduced testosterone levels [17]. As reduced QoL
could be a subtle sign of PI, we performed SF-36 testing
prior to surgery. We identified only a trend to a higher mean
values in patients with PI reduced QoL in brain tumor
patients is well described. We therefore believe that more
the brain tumor and less PI contribute to the identified
disorders.
Limitations of the study
We assumed that hypocortisolism and hypothyreoidism in
the 25 patients, which had been pre-treated with either
dexamethasone or L-thyroxine, represent drug effect and
not PI. In those patients, no stimulation test was performed,
which might have the potential to underestimate PI. As
reported by Hartman et al., the insulin tolerance test is the
classical test for the diagnosis of GH deficiency [27]. Since
we only registered basal IGF-1 and performed pituitary
stimulation with GHRH, we might have underestimated the
proportion of patients with GH deficiency. We only
examined blood samples preoperatively and on the first
and seventh postoperative day. We did not perform follow-
up investigations, which might have added further infor-
mation about the possible impact of adjuvant radio- and
chemotherapy on pituitary dysfunction as described by
Schneider et al. and other investigators [4, 12, 28–30].
Conclusion
PI is not infrequent in patients undergoing surgery for brain
tumors in distance to the hypothalamic–hypophyseal region.
As PI could already be diagnosed prior to surgery, PI is not
related to surgery but to other not yet identified factors.
Reduced QoL in patients with supratentorial tumors are
more frequent than PI. Organic brain tissue changes seem
to play a more important role for the development of QoL
reduction than PI.
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Comments
Alvaro Campero, Tucumán, Argentina
Nachter et al. performed a prospective trial in 54 patients with
supratentorial non-sellar tumor surgery. They studied the function of
the pituitary gland preoperatively and on days 1 and 7 after the
surgery. The authors found out that before the surgery, 44.4% of the
patients already had pituitary insufficiency. They also realized that
after the surgery, on days 1 and 7, the hormone profile showed no
changes. Thus, the authors rule out that the cause of pituitary
insufficiency in the postoperative period in patients operated on
supratentorial non-sellar tumors is the surgery itself. Further research
should be carried out in order to state if the percentage of biochemical
pituitary insufficiency in patients with brain tumors (outside the sellar
and parasellar region) is similar, greater, or lower, in relationship with
the general population or, perhaps, with other pathologies. Moreover,
further research should clarify the factors causing preoperative
pituitary insufficiency in brain tumors. Beyond the fact that some
questions still remain unanswered, the article of Watcher et al. is
original and contributes to the understanding of this most important
topic.
Ilonka Kreitschmann-Andermahr, Erlangen, Germany
The present study aimed to investigate if operations of brain
tumors distant to the hypothalamo-pituitary region actually cause
hypopituitarism. This is an important topic with potentially far
reaching implications for post-surgical patient care. The prospective
study design chosen by the authors is definitely the superior approach
to the few cross-sectional studies which have only assessed hormone
status after the intervention. However, the readers of this journal with
a predominantly neurosurgical and not endocrinological background
deserve to be assured about the soundness of the chosen methods and
the meaningful interpretation of laboratory results in relationship to
clinical parameters. To collect a range of basal hormone values in an
inhomogeneous and in part severely ill and heavily medicated patient
group before and after surgery, to combine these only in selected
circumstances with endocrine function tests, and to diagnose pituitary
insufficiency by imprecisely defined cut-off values is a questionable
methodological choice. Making an endocrine diagnosis this way
carries the risk of oversimplification and misinterpretation.
The authors acknowledged that many patients in the study group
received drugs with known influence on central and peripheral
hormone secretion and that numerous clinical conditions may impact
upon the pituitary and peripheral hormone secretion. Furthermore,
severe illness of any etiology is known to be accompanied by low T3
and low TSH levels. Opioids, antidepressants, neuroeptics, and
antiepileptics as well as epilepsy itself, but also obesity may have a
negative impact on the hypopituitary–gonadal axis. Insulin-like
growth factor I (IGF-I) can at best be considered a marker of impaired
GH secretion if, i.e., malnutrition, liver failure, poorly controlled
diabetes mellitus, or uremia are ruled out. Patients with current
dexamethasone therapy were precluded from evaluation of the
corticotroph axis, but also pretreatment with corticosteroids in the
weeks prior to the study might still corrupt the evaluation of the
pituitary–adrenal axis. Hyperprolactinemia is well known to be caused
by psychiatric medication as well as mental or physical stress.
It appears questionable to label the abnormal hormone values
found as “pituitary insufficiency”. The eight patients with elevated
IGF-I levels in the study population would in analogy have to be
defined as having acromegaly. Whether it is meaningful to set these
hormone levels in relation to neuroradiological findings or quality of
life, results must remain open. The present study tells us that elderly,
severely ill, and medicated patients may have abnormal hormone
laboratory results prior to and after neurosurgery, but conclusions
beyond that finding should be drawn cautiously and would have to be
substantiated further.
Jens Schittenhelm, Tübingen, Germany
Wachter et al. demonstrate that pituitary insufficiency is frequently
(44.8%) seen preoperatively in brain tumor patients and that hormone
Neurosurg Rev (2011) 34:509–516 515levels remain stable within the first week after surgery. This is
important because several studies have drawn the conclusion that
surgery distant from the sellar region might be causative for pituitary
insufficiency. Their results warrant future studies examining other
cancer patients undergoing surgery outside the brain and patients
without cancer undergoing brain surgery as control groups as the
factors that are causative remain to be identified. In patients with
recurrent malignant brain tumors, attention on previous radiation
therapy is needed. It is known that adults may demonstrate pituitary
deficiencies even in cases where the focus is outside hypothalamic–
pituitary axis [1, 2]. The high rate of preoperative medication with
potential effect on pituitary function might also account for the
preoperative insufficiency rate. The findings in this study also
emphasize that the presence of pituitary insufficiency further influen-
ces quality of life and are in line with other observations in this field
[3].
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